Qiagen Gdańsksp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2023-09-01
Share capital
1,752,650.00 PLN
Registered address
ul. Trzy Lipy 3/2.58, 80-172 Gdańsk, Poland
Electronic delivery address
AE:PL-83849-71995-HAEIB-33

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 2 of 2 financial statements were filed late (the longest delay 161 days for 2023). All were audited by a statutory auditor.

  • 2025not filed
  • 202406/10/2025
  • 202323/12/2024
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue
This companyUSD 4.19mMedianUSD 55.24kAverageUSD 2.71m
Net profit
This companyUSD -3.39mMedianUSD -1.27kAverageUSD -91.85k
Operating costs
This companyUSD 6.47mMedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 9.12mMedianUSD 133.19kAverageUSD 3.03m

Public procurement

2 tenders recorded as contractor, with a total value of $15,473.

SubjectAmount
Supply of chemical and laboratory reagents
$3,898
Supply of laboratory reagents.
$11,575

Authorized Representatives

Justyna Bernat – Attorney-in-fact (sole)
Katarzyna Spirin Polak – Management Board Member
Roland Sackers – Management Board Member

Manner of representation

1. When the management board is a one-person management board – the President of the Management Board or another member of the management board. 2. In the case of a multi-member management board – each member of the management board independently.

Ownership

OwnerSharesShare valueStake
Qiagen N.v.
35,053$473,433.28100%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2008-02-07.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Sep 19, 2023Transformation

Public aid

16 public aid cases recorded, with a total value of $218,100.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
–
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
–
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
–

European Funds

4 projects co-financed from European Funds recorded, with total EU co-financing of $2,889,716.

ProjectEU co-financing
Implementation of an innovative production technology for high-quality recombinant Proteinase K Ultra with properties used in clinical diagnostics by Blirt SA from Gdańsk
$139.7K
Development of a manufacturing technology and production of three recombinant enzymes (thermolabile dsDNase, a nonspecific nuclease that cleaves every form of nucleic acid and exhibits optimal activity below 20°C, and a fusion DNA polymerase linked to a DNA-binding protein).
$82,759
Liquid and lyophilised Master Mixes for FAST-type Real-Time PCR reactions.
$55,794

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
InventionbioS.A.
MedappS.A.
BiotechnaS.A.
Read-GeneS.A.
Proteon PharmaceuticalsS.A.
SkinlabP.S.A.
EIT Rawmaterials Clc Eastsp. z o.o.
Centrum Innowacji I Wdrożeń Bio-Inwestsp. z o.o.
COS LabP.S.A.
Syventosp. z o.o.

FAQ

Last updated: 2026-10-03